Neuroprotective role of Indirubin-3′-monoxime, a GSKβ inhibitor in high fat diet induced cognitive impairment in mice

Biochemical and Biophysical Research Communications

Volumn 452, Issue 4, 2014, Pages 1009-1015

  Sharma, Sorabh ^a   Taliyan, Rajeev ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Alzheimer's disease; Cognitive deficit; GSK3 ; Insulin resistance; Oxidative stress

Indexed keywords

ACETYLCHOLINESTERASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; GLUTATHIONE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INDIRUBIN 3' MONOXIME; INSULIN; MALONALDEHYDE; NEUROPROTECTIVE AGENT; NITRITE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDIRUBIN-3'-MONOXIME; INDOLE DERIVATIVE; OXIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN LEVEL; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN BRAIN LEVEL; INSULIN RESISTANCE; LIPID DIET; LOCOMOTION; MALE; MEMORY; MOUSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PASSIVE AVOIDANCE; SPATIAL LEARNING; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; DIET, HIGH-FAT; GLYCOGEN SYNTHASE KINASE 3; INDOLES; INSULIN RESISTANCE; MALE; MICE; NEUROPROTECTIVE AGENTS; OXIMES; TREATMENT OUTCOME;

EID: 84907903766     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.09.034     Document Type: Article

References (31)

1. S. Takeda, N. Sato, and H. Rakugi Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function Mol. BioSyst. 7 2011 1822 1827
2. S.J. Roriz-Filho, T.M. Sá-Roriz, and I. Rosset (Pre)diabetes, brain aging, and cognition Biochim. Biophys. Acta 1792 2009 432 443
3. T. Matsuzaki, K. Sasaki, and Y. Tanizaki Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama Study Neurology 75 2010 764 770
4. K. Talbot, H.Y. Wang, and H. Kazi Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J. Clin. Invest. 122 2012 1316 1338
5. W.Q. Zhao, H. Chen, and M.J. Quon Insulin and the insulin receptor in experimental models of learning and memory Eur. J. Pharmacol. 490 2004 71 81
6. C. Hooper, R. Killick, and S. Lovestone The GSK3 hypothesis of Alzheimer's disease J. Neurochem. 104 2008 1433 1439
7. K. Leroy, Z. Yilmaz, and J.P. Brion Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration Neuropathol. Appl. Neurobiol. 33 2007 43 55
8. E.M. Blalock, J.W. Geddes, and K.C. Chen Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses Proc. Natl. Acad. Sci. USA 101 2004 2173 2178
9. T. Engel, P. Goni-Oliver, and J.J. Lucas Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J. Neurochem. 99 2006 1445 1455
10. K. Srinivasan, B. Viswanad, and L. Asrat Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol. Res. 52 2005 313 320
11. H.N. Yadav, M. Singh, and P.L. Sharma Pharmacological inhibition of GSK-3β produces late phase of cardioprotection in hyperlipidemic rat: possible involvement of HSP 72 Mol. Cell. Biochem. 369 2012 227 233
12. S. Akagiri, Y. Naito, and H. Ichikawa A mouse model of metabolic syndrome; increase in visceral adipose tissue precedes the development of fatty liver and insulin resistance in high-fat diet-fed male KK/Ta mice J. Clin. Biochem. Nutr. 42 2008 150 157
13. R. Deshmukh, V. Sharma, and S. Mehan Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor Eur. J. Pharmacol. 620 2009 49 56
14. R.G.M. Morris Development of a water-maze procedure for studying spatial learning in the rats J. Neurosci. Methods 11 1984 47 60
15. O.H. Lowry, N.J. Rosebrough, and A.L. Farr Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
16. G.L. Ellman, K.D. Courtney, and V. Andres A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
17. E.D. Wills Mechanism of lipid peroxide formation in animal Biochem. J. 99 1996 667 676
18. L.C. Green, D.A. Wagner, and J. Glgowski Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids Ann. Biochem. Exp. Med. 126 1982 131 135
19. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
20. A.D. McNeilly, R. Williamson, and D.J.K. Balfour A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin Diabetologia 55 2012 3061 3070
21. A.K. Datusalia, and S.S. Sharma Amelioration of diabetes-induced cognitive deficits by GSK-3â inhibition is attributed to modulation of neurotransmitters and neuroinflammation Mol. Neurobiol. 2014 [Epub ahead of print]
22. A.R. Pathan, A.B. Gaikwad, and B. Viswanad Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats Eur. J. Pharmacol. 589 2008 176 179
23. M.I. Miranda, G. Ferreira, and L. Ramirez-Lugo Role of cholinergic system on the construction of memories: taste memory encoding Neurobiol. Learn. Mem. 80 2003 211 222
24. M.M. Mesulam, and M.M. Asuncion Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease Ann. Neurol. 22 1987 223 228
25. J.L. Evans, I.D. Goldfine, and B.A. Maddux Are oxidative stress-activated signalling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52 2003 1 8
26. M. Padurariu, A. Ciobica, and L. Hritcu Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease Neurosci. Lett. 469 2010 6 10
27. C.B. Pocernich, and D.A. Butterfield Elevation of glutathione as a therapeutic strategy in Alzheimer disease Biochim. Biophys. Acta 2012 1822 625 630
28. S.H. Koh, Y.B. Lee, and K.S. Kim Role of GSK-3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene Eur. J. Neurosci. 22 2005 301 309
29. S. Craft, L.D. Baker, and T.J. Montine Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch. Neurol. 69 2012 29 38
30. H.S. Phillips, J.M. Hains, and M. Armanini BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease Neuron 7 1991 695 702
31. A. Patapoutian, and L.F. Reichardt Trk receptors: mediators of neurotrophin action Curr. Opin. Neurobiol. 11 2001 272 280